Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 72-year-old man is evaluated in the hospital on day 4 of an admission for a severe exacerbation of chronic obstructive pulmonary disease (COPD). He originally presented with dyspnea, wheezing, and a productive cough. His home medications include inhaled tiotropium, as-needed albuterol, and warfarin for a mechanical mitral valve (target INR 2.5-3.5). Upon admission, he was started on intravenous methylprednisolone, nebulized ipratropium-albuterol, and oral levofloxacin. Today, his dyspnea has completely resolved, and he is breathing comfortably on room air. He reports no chest pain, palpitations, or signs of bleeding. Vital signs are temperature 37.1°C (98.8°F), pulse 82/min, respirations 14/min, and blood pressure 128/78 mm Hg. Laboratory studies obtained this morning show:

Hemoglobin: 13.5 g/dL
Platelet count: 210,000/mm³
Serum creatinine: 1.1 mg/dL
Prothrombin time (PT): 48 seconds
International normalized ratio (INR): 6.2

Which of the following is the most appropriate next step in the management of this patient?

  1. Omit the next dose of warfarin and recheck the international normalized ratio tomorrowCevap
  2. B
    Administer intravenous vitamin K and fresh frozen plasma
  3. C
    Discontinue levofloxacin and initiate trimethoprim-sulfamethoxazole
  4. D
    Order computed tomography angiography of the chest
  5. E
    Transfer the patient to the intensive care unit for continuous monitoring

Cevap

Omit the next dose of warfarin and recheck the international normalized ratio tomorrow
The patient has a supratherapeutic INR (6.2) without any clinical signs of bleeding. The elevation in INR was likely precipitated by the recent initiation of levofloxacin, which can enhance the anticoagulant effect of warfarin by altering intestinal flora and reducing vitamin K production. According to the American College of Chest Physicians (ACCP) guidelines, for a patient with an INR between 4.5 and 10.0 and no evidence of active bleeding, the most appropriate management is to simply withhold the next 1 to 2 doses of warfarin, monitor the INR closely, and resume therapy at a properly adjusted dose once the INR returns to the therapeutic range. Routine administration of oral or intravenous vitamin K is not recommended in this scenario, as it does not improve clinical outcomes and can cause a prolonged period of subtherapeutic anticoagulation.

Adım Adım Çözüm

1
Assess the patient's clinical stability and bleeding status.
The patient is hemodynamically stable, his initial respiratory symptoms have resolved, and he has no signs of active bleeding.
The presence or absence of active bleeding dictates the urgency and aggressiveness of anticoagulation reversal.
2
Interpret the laboratory findings in the context of recent medication changes.
The patient has a supratherapeutic INR of 6.2, likely potentiated by the recent addition of levofloxacin.
Identifying the etiology of the elevated INR helps guide management and prevents future over-anticoagulation once therapeutic levels are re-established.
3
Apply standard treatment guidelines for supratherapeutic INR.
For an INR between 4.5 and 10.0 without evidence of bleeding, the standard recommendation is to hold the next 1 to 2 doses of warfarin.
This strategy allows the INR to naturally decline into the therapeutic range without exposing the patient to the risks associated with exogenous vitamin K or blood product administration.

Anahtar Kavram

In an asymptomatic patient taking warfarin who develops a supratherapeutic INR between 4.5 and 10.0 without active bleeding, the appropriate management is to withhold the next 1 to 2 doses of warfarin, monitor closely, and avoid routine administration of vitamin K or fresh frozen plasma.
Tahmini Süre:1m 15s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru